Akari Therapeutics (NASDAQ:AKTX) Upgraded at Maxim Group

Maxim Group upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a hold rating to a buy rating in a research report released on Monday, Marketbeat reports. The brokerage currently has $30.00 price target on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Wall Street Zen raised Akari Therapeutics to a “sell” rating in a research report on Saturday, June 27th. HC Wainwright lifted their target price on Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Finally, Weiss Ratings upgraded Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.

Akari Therapeutics Stock Up 5.5%

AKTX opened at $9.81 on Monday. Akari Therapeutics has a 12 month low of $3.02 and a 12 month high of $49.60. The firm’s fifty day simple moving average is $12.04 and its 200 day simple moving average is $9.42.

Institutional Trading of Akari Therapeutics

A hedge fund recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.